Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

Sandip Ray, Markus Britschgi, Charles Herbert, Yoshiko Takeda-Uchimura, Adam Boxer, Kaj Blennow, Leah F. Friedman, Douglas R. Galasko, Marek Jutel, Anna Karydas, Jeffrey A. Kaye, Jerzy Leszek, Bruce L. Miller, Lennart Minthon, Joseph F. Quinn, Gil D. Rabinovici, William H. Robinson, Marwan N. Sabbagh, Yuen T. So, D. Larry SparksMassimo Tabaton, Jared Tinklenberg, Jerome A. Yesavage, Robert Tibshirani, Tony Wyss-Coray

Research output: Contribution to journalArticlepeer-review

894 Scopus citations


A molecular test for Alzheimer's disease could lead to better treatment and therapies. We found 18 signaling proteins in blood plasma that can be used to classify blinded samples from Alzheimer's and control subjects with close to 90% accuracy and to identify patients who had mild cognitive impairment that progressed to Alzheimer's disease 2-6 years later. Biological analysis of the 18 proteins points to systemic dysregulation of hematopoiesis, immune responses, apoptosis and neuronal support in presymptomatic Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)1359-1362
Number of pages4
JournalNature medicine
Issue number11
StatePublished - Nov 2007

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins'. Together they form a unique fingerprint.

Cite this